Norcodeine, Urine
Norcodeine is the N-demethylated metabolite of the parent drug known as codeine. However, norcodeine does not elicit any clinical pharmacologic effects as codeine. Approximately after 3 days of codeine use, the metabolites found in a urine specimen are similar to that following morphine or heroin use, but if norcodeine is found in the urine than this metabolite is indicative of codeine use but this alone cannot exclude concomitant morphine use.
Since norcodeine does not elicit any pharmacologic effects as most of the other opioids, it is not used by drug abusers. Norcodeine can be analyzed by a variety of analytical methods such as Gas Chromatography/Mass Spectroscopy (GC/MS), Liquid Chromatography/Mass Spectroscopy (LC/MS), Immunoassay, and screening spot testing.
- Drug abuse evaluation
- Toxicity assessment
- Patient Compliance
Therapeutic Level: N/A
Toxic level: N/A
Note: therapeutic ranges and toxic thresholds are best evaluated from blood samples. Quantitative results obtained with blood samples collected at specific times after drug administration are preferred for pharmacokinetic analyses.
Cut-Off Ranges
Cut-off values can vary based on the particular method of analysis that is used for detection by a quantitative method, such as LC/MS or GC/MS. The testing laboratory cut-off range is listed on the patient report. Consult your physician for further information or click on one of the references that are listed below.
Fresh urine specimen collected in either a clean glass or plastic container. An acceptable urine specimen submitted for testing should be in the pH range of 3-11. Adulteration of the urine specimen can result in erroneous results.
Serum specimens that are collected in a non-gel red top tube are the preferred specimens of choice. Plasma specimens are acceptable if drawn in a heparin (green top) tube. Specimens should be spun and the serum or plasma separated and refrigerated.
Stability
- Ambient: 3-5 days
- Refrigeration: 5-7 days
- Frozen: 30 days
- Baselt RC (ed). Analytical procedures for therapeutic drug monitoring and emergency toxicology, 2nd ed. Littleton, MA: PSG Publishing Co.; 1987.
- Baselt RC (ed). Disposition of toxic drugs and chemicals in man, 9th ed. Foster City, CA: Biomedical Publications; 2011.
- Baselt RC (ed). Disposition of toxic drugs and chemicals in man, 6th ed. Forster City, CA: Biomedical Publications; 2002.
- Gupta RN. Review: drug level monitoring: sedative hypnotics. J Chromatography. 1985;340:139-72.
- Levine B (ed). Principles of Forensic Toxicology, 4th ed. Washington DC: AACC Press. Chapter 25, Antihistamines pp. 435-440; 2013.
- Brunton LL, Chabner B, Knollman B, eds. Goodman and Gilmans’ the pharmacological basis of therapeutics, 12th ed. New York: McGraw-Hill; 2010.
- Cooper FJ, Logan BK. Drugs and human performance fact sheets. Washington, DC: National Highway Traffic Safety Administration, U.S. Department of Transportation. DOT HS 809 725; 2004.
- Katzung BG, Masters S, Trevor AK (eds). Basic and clinical pharmacology, 12th ed. New York: McGraw-Hill; 2011.
- Stout PR, Farrell LJ. Opioids – Effects on human performance and behavior. Forensic Sci Rev. 2002;15:29-59.
- Wu A (ed). Tietz, clinical guide to laboratory test, 4th ed. Philadelphia: WB Saunders; 2006.